The Biostar Technology Research Institute announced on the 7th that the Osaka Trinity Clinic, a cooperative hospital in Osaka, Japan, has received approval from the Japanese Ministry of Health, Labor and Welfare for autism regeneration treatment using biostar’s autologous fat-derived mesenchymal stem cells.
Autistic patients will be able to perform regenerative medical treatment using biostar autologous fat-derived mesenchymal stem cells at the Osaka Trinity Clinic under the approval of the treatment. Autologous fat-derived mesenchymal stem cells are known to promote the regeneration of damaged cranial nerve tissue as well as immunomodulatory and neuroprotective effects.
In patients diagnosed with autism aged 4 or older, intravenous stem cell administration is carried out, and 50 million to 300 million cells are administered at intervals of 2 to 4 weeks over a total of 5 to 10 times per treatment. Using SRS-2, a standard assessment tool for autism spectrum disorder, safety and effectiveness are measured objectively at 3 months after the final administration.
Stem cells for the treatment of autism are provided by R-Bio, which receives culture media from Nature Cells, and JASC, Japan.
Biostar said it was the first in the world to confirm that key symptoms of autism spectrum disorders, such as repetitive behavior, social deficiency, and anxiety, improved significantly after administration of autologous fat-derived mesenchymal stem cells in a valproic acid-induced autistic mouse model, and published related research results in the SCI-level International Brain Research.
Dr. Ra Jeong-chan, director of the Biostar Institute of Technology, said, “Through the approval of Japan’s welfare, many patients and families from all over the world will come to Japan and receive treatment with Korea’s stem cell technology. We will consider accelerating the development of new drugs in the United States by collecting scientific data before and after treatment.”
SAM KIM
US ASIA JOURNAL
